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ABSTRACT
Background: Microparticles (MPs) are plasma membrane-derived extracellular 
vesicles present in the bloodstream. We have described a specific signature of MPs, 
called microparticulosome, in colorectal (CRC) and pancreatic (PC) cancers. We 
observed that levels of fibrin-bearing MPs were significantly increased in patients 
suffering from PC and CRC in comparison with control groups. Here, we hypothesised 
that fibrin-MPs may constitute a relevant biomarker of thrombosis associated with 
cancer. The objective was to compare the microparticulosome signature between 
patients presenting with thrombo-embolic event and those without.
Methods: Patients with CRC and PC were prospectively included and divided in 
those with thrombo-embolic events (Group A) and those without (Group B).
MPs were analyzed by flow cytometer, combining the analysis of Annexin 
V-positive with characterization of their origin and determination of their procoagulant 
activities. D-dimer levels were measured in the same samples.
Results: We included 118 patients, divided in 19 patients with thrombo embolic 
event and 99 patients without. Fibrin-bearing MPs levels were significantly higher in 
presence of thrombo-embolic events, contrary to D-dimers levels. Fibrin-bearing MPs 
were more frequently produced by erythrocytes, endothelial cells or Ep-CAM+cells 
than platelets or leukocytes. Overall survival was shorter in case of thrombo-embolic 
events than without. The most frequent genes expressed by MPs derived from PC 
or CRC were implicated in metastatic diffusion of tumor cells, drug resistance, 
coagulation and inflammation.
Conclusion: Circulating MPs, particularly fibrin-bearing MPs, could be used as 
a new biomarker to predict cancer-associated thrombo-embolic events and poor 
survival.
INTRODUCTION
Cancer-associated venous thromboembolism (VTE) 
causes significant morbidity and mortality in patients, 
given that it constitutes the second most common of death, 
after the progression of the cancer itself. Cancer-associated 
VTE was firstly described in 1823 by Jean-Baptiste 
Bouillard and, in 1865 by Armand Trousseau [1]. Defined 
as deep vein thrombosis and/or pulmonary embolism, 
VTE occurs more frequently in case of pancreatic ((PC) 
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5.3%-26%) or brain (1.6-26%) cancers [2]. Many series 
have reported the poor prognosis of PC in presence of 
VTE [3-6].
Many risk factors for cancer-associated VTE have 
been identified, such as patient characteristics (history 
of VTE, obesity, immobilization), tumor characteristics 
(location, metastatic), anti-cancer treatments, blood 
cells (platelet, leukocyte, neutrophil extracellular traps), 
and hypercoagulable state (thrombin-antithrombin 
complexes, prothrombin fragment, factor VIII, D dimer, 
soluble P-selectin, Tissue Factor (TF), microparticles 
(MPs)). Particularly, Khorana et al demonstrated that the 
occurrence of VTE in PC seems to be correlated with the 
plasma levels of soluble activated Tissue Factor (TF) [7].
The MPs are heterogeneous extracellular vesicles 
(0.1-1.0 μm), produced by budding and fission of the 
plasma membrane from many eukaryotic cells in response 
to cellular activation (inflammation, cancer) or apoptosis, 
and express on their surface anionic phospholipids (mainly 
phosphatidylserine (PS)), cellular origin antigens, and 
different effectors [8, 9]. They are known to be involved 
in procoagulant and fibrinolytic activities, vascular 
remodeling, or neoangiogenesis, through such effectors 
on their surface as TF and PS, plasminogen activators, 
inflammatory cytokines, or vascular endothelial growth 
factor, respectively. In case of cancer, different reports 
have identified circulating MPs as a main source of TF 
responsible for thrombosis. These procoagulant MPs may 
originate from cancer cells themselves and participate not 
only in the procoagulant state by generating thrombin 
and fibrin but may also be actively involved in the tumor 
behaviour and formation of metastasis [10, 11]. To date, 
different reports have studied the use of TF-bearing MPs 
as a biomarker of thrombosis in cancer [12]. However, the 
results of these studies are contradictory with increased 
levels of TF-bearing MPs in presence of PC-associated 
VTE [13, 14] and increased procoagulant activity of 
cancer-associated MPs, in absence of VTE [15-19], or in 
case of cancer-associated VTE [13, 14, 20-22].
Recently, we described a MPs signature, named 
the “microparticulosome”, in colorectal cancer (CRC) 
and PC, compared to inflammatory bowel or pancreatic 
diseases and healthy subjects [23]. In this study, a 
significant increase in fibrin-bearing MPs in PC patients 
was observed compared to the other groups, in accordance 
with the higher risk of thrombosis in this cancer. However, 
no significant variation of TF-bearing MPs was noted 
between groups [23].
Therefore, based on our results previously described 
and, as the final product of the coagulation cascade is 
fibrin, we consider that fibrin-bearing MPs may constitute 
an efficient marker to evaluate the procoagulant activity of 
cancer-derived MPs.
The aim of the present study was thus to compare 
the microparticulosome between patients presenting with 
thrombo-embolic event associated with CRC and PC, and 
those without thrombo-embolic event.
RESULTS
Study population with or without thrombo-
embolic event
We included 118 patients presenting with CRC and 
PC, divided as following:
- In Group A (thrombo-embolic event), 19 patients 
including 10 CRC and 9 PC. In 14 patients, it was a 
venous thrombo-embolism (deep vein thrombosis n=7, 
pulmonary embolism n=7). In the last 5 patients, it was 
an arterial thrombo-embolic event, with cerebral vascular 
accident (n=4) and thrombosis of the femoral artery (n=1).
- In Group B (without thrombo-embolic event), 99 
patients including 74 CRC and 25 PC.
There was no significant difference between groups 
regarding to the demographic data and the stage of the 
cancers (Table 1).
Comparison of MPs levels
Total MPs were higher in Group A (8989 [1157-
2,119*106] MPs/ μL) than in Group B (5866 [865–355459] 
MPs/ μL, p=0.17), without significant difference. There 
was no significant difference of MPs levels regarding to 
the different subpopulations of MPs (vs PMPs, EMPs, 
EryMPs, LeuMPs) (Table 2). TF bearing MPs levels were 
similar between groups (107 [0–1164] MPs/ μL versus 
94 [0–3980] MPs/ μL p=0.48), whereas Fibrin bearing 
MPs levels were significantly higher in Group A (143 
[0–1125] MPs/ μL) than in Group B (40 [0–930] MPs/ 
μL, p=0.01) (Figure 1). The Area Under Curve (AUC) 
for fibrin bearing MPs was 0.67 (p=0.01), demonstrating 
a good performance of this parameter in prediction of 
thromboembolic event (Figure 2). The threshold value 
with highest intrinsic characteristics (Sensibility = 68%, 
Specificity = 64%) was equal to 55 Fibrin-bearing MPs/ 
μL. The different tumor MPs levels were significantly 
lower in Group A than in Group B.
When we compared the occurrence of thrombo 
embolic event according to the type of cancer, we 
observed the same tendency for the different MPs without 
significant difference, probably due to the small size 
samples. In CRC and PC, total MPs, PMPs, EMPs, and 
Fibrin-bearing MPs levels were higher in presence of 
thromboembolic events than without (Table 3). In CRC, 
tumor MPs such as MUC1-, ACE- and CA19-9 bearing 
MPs, were significantly less observed in case of thrombo 
embolic event (0 [0–57], 0 [0–23] and 0 [0–0] MPs/ μL 
respectively) than without (15 [0–6673] MPs/ μL, p=0.02; 
20 [0–1850] MPs/ μL, p=0.002; and 21 [0–4337] MPs/ 
μL, p=0.0009, respectively). Taken together these results 
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indicate that fibrin-bearing MPs levels are an efficient 
marker of cancer-associated thrombo-embolic event.
Origin of Fibrin+ MPs
In PC samples, fibrin-bearing MPs derived more 
frequently from erythrocytes (102 [0–15813] MPs/ 
μL), endothelial cells (61 [0–967] MPs/ μL) or Ep-
CAM+ cells (48 [0–15793] MPs/ μL) than platelets (5 
[0–16562] MPs/ μL) or leucocytes (2 [0–6756] MPs/ 
μL; p<0.0001).
D-dimer levels
Median D-dimer levels were higher in Group A 
(1170 [192–13050] ng/mL) than Group B (551 [54–4745] 
ng/mL), but this difference was not significant (p=0.1). 
According to the type of cancer, there was no significant 
difference in median D-dimer levels in case of thrombo-
embolic event or not: 1170 [237 -2817] vs 564 [54–4686] 
ng/mL (p= 0.1) in CRC, and 1031 [192–13050] vs 378 
[56–4745] ng/mL (p=0.5) in PC.
Overall survival and thrombo embolic event
Median overall survival was shorter in presence 
of thrombo embolic event (9 months) than without 
(28 months), but the difference was not statistically 
significant (p=0.2; Figure 3). This result indicates that 
thrombo-embolic event associated with cancer could be 
associated with a poor prognosis. Moreover, we have 
compared overall survival according to the threshold 
value of 55 Fibrin-bearing MPs/ μL (Figure 4): median 
survival was shorter in with levels > 55 MPs/ μL (14 
months) than ≤ 55 MPs/ μL (28 months), without reach 
significance (p=0.07).
Table 1: Demographic data of the 118 patients presenting with colorectal or pancreatic cancer, according to the 
occurrence or not of a thrombo-embolic event
Group A Group B
Thrombo-embolic event No thrombo embolic event
n 19 99 P value
Gender 0.79
Male 12 (63) (a) 67 (68)
Female 7 (37) 31 (32)
Age (years) 69 [54–89] (b) 71 [29–93] 0.32
Colorectal cancer 10 (53) 74 (75)
TNM stage (c)
0 - 6 (8) 0.89
I 2 (20) 17 (23)
II 3 (30) 22 (30)
III 3 (30) 17 (23)
IV 2 (20) 12 (16)
Pancreatic cancer 9 (47) 25 (25)
TNM stage
I - 1 (4) 0.19
II 7 (78) 12 (48)
III - 2 (8)
IV 1 (11) 7 (28)
NA 1 (11) 3 (12)
(a): number (percentage); (b): median (range); (c): TNM, i.e. Tumor Node Metastasis, classification includes stages I and II for 
localized tumor, III for locally advanced and IV for metastatic tumor; NA: not available; p<0.05 is considered as significant.
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Table 2: Microparticulosome signature based on a color code: high (red) and low (green) levels of MPs (MPs/ μL of 
plasma), according to the occurrence or not of a thrombo-embolic event
Group A Group B
Thrombo-embolic event No thrombo embolic event
n 19 99 P value
Total MPs
8989(a)
[1157–2119000]
(100%)
5866
[865–355459]
(100%)
0.17
Subpopulations
PMPs
5021
[110–32515]
(56%)(b)
3543
[288–45959]
(61%)
0.28
EMPs
16
[1.1-1507]
(0.2%)
3
[0.6-2340]
(0.05%)
0.17
EryMPs
126
[0–6641]
(1%)
260
[0–13026]
(4%)
0.65
LeuMPs
3
[0–44]
(0.03%)
5
[0–2972]
(0.08%)
0.43
Procoagulant MPs
TF positive
107
[0–1164]
(1%)
94
[0–3980]
(2%)
0.48
Fibrin positive
143
[0–1125]
(2%)
40
[0–930]
(0.7%)
0.01
Tumor MPs
PODOPLANIN positive
37
[0–4060]
(0.4%)
49
[0–6456]
(0.9%)
0.24
MUC1 positive
0
[0–57]
(0.07%)
8
[0–6673]
(0%)
0.002
CEA positive
0
[0–284]
(0%)
21
[0–4497]
(0.4%)
<0.0001
CA19-9 positive
0
[0–786]
(0%)
31
[0–4337]
(0.6%)
0.01
(a) median (range); (b) percentage of MPs’ subtypes out of median total MPs; p<0.05 is considered as significant; Total MPs 
= Annexin V+ MPs; PMPs = platelet-derived MPs (Annexin V+/CD41+); EMPs = endothelial-derived MPs (Annexin V+/
CD31+/CD41-);
EryMPs = erythrocyte-derived MPs (Annexin V+/ CD235a+); LeuMPs = leukocyte-derived MPs (Annexin V+/CD11b+/
CD235a-); TF positive = Annexin V+/TF+;
Fibrin positive = Annexin V+/Fib+; MUC positive = AnnexinV+/MUC+; CEA positive = AnnexinV+/CEA+; CA 19-9 
positive = Annexin +/CA19-9 +.
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Analysis of RNA profile PC- and CRC-derived 
MPs
In PC-derived MPs, the most frequently expressed 
genes were ANXA5 (delta CT=8), ITGB1 (delta CT=9), 
ADRB2 (delta CT=10), ANXA1 (delta CT=10), HPGD 
(delta CT=11) and NFKB1 (deltaCT=10).
Similarly, the most frequently expressed genes in 
CRC-derived MPswere ANXA5 (delta CT=8), ITGB1 
(delta CT=10), ANXA1 (delta CT=13), NFKB1 (delta 
CT=13), MAPK14 (delta Cycle Threshold (CT) =12) and 
MAPK8 (delta CT=13).
These genes are known to be implicated in 
proliferation (MAPK8), metastatic diffusion of tumor 
cells (ITGB1), drug resistance (ANXA1), coagulation 
(ANXA3, ANXA5) or inflammation (HPGD, NFKB1).
DISCUSSION
We have reported that circulating MPs levels varied 
in presence of thrombo-embolic event associated with 
CRC or PC. Particularly, fibrin-bearing MPs levels were 
significantly higher in presence of thrombo-embolic 
event associated with CRC or PC than without. Overall 
survival was shorter in case of thrombo-embolic event 
than without.
We did not observe any variation of MPs-TF levels 
in presence of thrombo-embolic event, neither between 
different pathological groups in our microparticulosome 
[23]. Conflicting results about MPs-TF levels are reported 
in the literature. [13, 14, 19, 26, 27]. This is probably due 
to lack of standard assay for measuring TF expression 
and activity on MPs, between immunohistochemical TF 
staining, enzyme-linked immunosorbent assay, MPs-
TF activity assays, and flow-cytometry based methods. 
Furthermore, an associated explanation may be the 
quiescent state of the TF on the MPs. Following an injury, 
TF-expressing cells will accumulate at the site of injury 
leading to the activation of the blood coagulation cascade. 
The mechanisms involved in the activation of TF are still 
unclear. One hypothesis consists in the activation of TF 
by the protein disulfide isomerase (PDI). PDI is the most 
abundant thiol isomerase, present in the endoplasmic 
reticulum, with oxydoreductase functions, forming or 
cleaving disulphide bonds. The hypothesis is thus that the 
mechanism of TF de-encryption (vs, activation) involves 
Figure 1: Levels of fibrin-bearing microparticles in case of thrombo embolic event (Group A) and without (Group B), 
in MPs/ μL.
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oxidation of 2 free sulphydryls and formation of a 
disulfide bond, and PDI may be the enzyme that catalyses 
the formation of that disulfide-bond [28, 29]. Last, for few 
authors, procoagulant activity of MPs is mainly due to 
the PS at their surface, as illustrated by higher inhibition 
of coagulation in presence of Annexin V or Lactadherin, 
which bind to PS, than in presence of anti-TF antibody 
[15, 16, 18].
As levels of circulating TF-bearing MPs seem not to 
be an excellent reflect of procoagulant activity of MPs for 
the different previous reasons, we have considered that, 
as the final product of the coagulation cascade is fibrin, 
the levels of fibrin-positive MPs may directly correlate 
with the activation state of the blood coagulation cascade. 
To our knowledge, we are thus the first to evaluate the 
procoagulant activity of MPs by quantifying the level of 
fibrin-bearing MPs. Indeed, in the current study, fibrin-
bearing MPs levels were significantly higher in presence 
of thrombo-embolic event associated with CRC or 
PC. Moreover, in our “microparticulosome”, we have 
observed significant increased fibrin-bearing MPs levels 
in the PC group compared to the other groups, which is 
in accordance with the higher risk of thrombo-embolic 
event in PC than in CRC [23]. In a recent case series, 
we reported the diagnosis of a breast cancer in a woman 
with polymyalgia rheumatic, thanks to elevated level of 
fibrin-bearing MPs [30]. In these different studies, we 
have used a standardized protocol based on citrated tubes, 
strict conditions for storage and preparation, adding of 
anticoagulant (i.e prostacyclin) and fixation of the sample 
(i.e formaldehyde), in order to avoid secondary activation 
of coagulation after blood collection. For these reasons, 
fibrin-bearing MPs levels may be an excellent reflect of 
the procoagulant activity of MPs from blood circulation, 
and not a product of in vitro coagulation. Ep-CAM is a 
membrane glycoprotein known to be overexpressed in 
cancers, such as PC [31], breast or lung [32] cancer. After 
confirmation of the Ep-CAM expression on PC associated 
MPs, we have observed that the origin of fibrin-bearing 
MPs is more frequently erythrocytes, endothelial cells 
or tumour cells (Ep-CAM+) than platelets or leukocytes. 
This result is in accordance with the implication of MPs in 
cancer associated thrombo-embolic events.
Some authors have demonstrated the prognosis 
impact of D-dimer levels on poor survival in ovarian 
cancer [33], renal cell carcinoma [34] or melanoma [35]. 
We did not report a significant difference in median 
D-dimer levels in case of thrombo-embolism event, in 
Figure 2: Receiving Operator Characteristics curve and Area under the Curve (AUC) for Fibrin-bearing MPs levels.
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Table 3: Microparticulosome signature based on a color code: high (red) and low (green) levels of MPs (MPs/ μL of 
plasma), according to the occurrence or not of a thrombo-embolic event, in colorectal and pancreatic cancers
Colorectal cancer Pancreatic cancer
Thrombo-
embolic event
No thrombo 
embolic event
Thrombo-
embolic event
No thrombo 
embolic event
n 10 74 P value 9 25 P value
Total MPs
7532 (a)
[1157–16942]
(100%)
5540
[865–53956]
(100%)
0.58
11920
[1855–2119000]
(100%)
6544
[1679–355459]
(100%)
0.39
Subpopulations
PMPs
4293
[856–11775]
(57%)(b)
3527
[822–45959]
(64%)
0.69
5131
[110–32515]
(43%)
3558
[288–44275]
(57%)
0.39
EMPs
8
[1.1-29]
(0.1%)
2
[0.6-836]
(0.04%)
0.52
102
[1.3-1507]
(0.9%)
45
[1–2340]
(0.7%)
0.33
EryMPs
113
[0–6641]
(1.5%)
264
[0–13026]
(5%)
0.40
448
[0–3832]
(4%)
207
[14–8155]
(3%)
0.78
LeuMPs
3
[0–15]
(0.03%)
4
[0–792]
(0.07%)
0.14
20
[0–44]
(0.2%)
8
[0–2972]
(0.1%)
0.75
Procoagulant MPs
TF positive
107
[0–967]
(1%)
81
[0–3980]
(1%)
0.62
93
[0–1164]
(0.8%)
126
[0–1268]
(2%)
0.86
Fibrin positive
101
[0–1125]
(1%)
40
[0–633]
(0.7%)
0.15
238
[0–411]
(2%)
41
[0–930]
(0.6%)
0.08
Tumor MPs
Podoplanin 
positive
20
[0–98]
(0.3%)
40
[0–6456]
(0.7%)
0.26
96
[0–4060]
(0.8%)
85
[0–988]
(1%)
0.5
MUC1 positive
0
[0–57]
(0%)
15
[0–6673]
(0.3%)
0.02
0
[0–11]
(0%)
0
[0–985]
(0%)
0.1
CEA positive
0
[0–23]
(0%)
20
[0–1850]
(0.4%)
0.002
0
[0–284]
(0%)
25
[0–4497]
(0%)
0.06
CA19-9 positive
0
[0–0]
(0%)
21
[0–4337]
(0.4%)
0.0009
0
[0–786]
(0%)
46
[0–777]
(0.7%)
0.64
(a) median (range); (b) percentage of MPs’ subtypes out of median total MPs; p<0.05 is considered as significant; Total MPs 
= Annexin V+ MPs; PMPs = platelet-derived MPs (Annexin V+/CD41+); EMPs = endothelial-derived MPs (Annexin V+/
CD31+/CD41-);
EryMPs = erythrocyte-derived MPs (Annexin V+/ CD235a+); LeuMPs = leukocyte-derived MPs (Annexin V+/CD11b+/
CD235a-); TF positive = Annexin V+/TF+;
Fibrin positive = Annexin V+/Fib+; MUC positive = AnnexinV+/MUC+; CEA positive = AnnexinV+/CEA+; CA 19-9 
positive = Annexin +/CA19-9 +.
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our overall study population and neither in CRC or PC 
subgroups.
Besides to the level of fibrin-bearing MPs, we 
observed a decrease of MUC1-bearing MPs in case of 
thrombo-embolic event, whereas two series reported 
increased levels of MUC1-bearing MPs in presence of 
VTE [13, 22]. However, our median levels of MUC1-
bearing MPs were very low (from 0 [0–57] to 8 [0–6673] 
MPs/ μL), contrary to Woei-A-Jin et al (from 0 [0–221] 
to 194 [27–392] MPs/ μL) [13]. Although anti-MUC1 
antibodies were different between our series (anti-
MUC1-647, Novocastra, Newcastle, UK) and the two 
Figure 3: Overall survival in case of thrombo embolic event (Group A) and without (Group B).
Figure 4: Overall survival according to threshold value of Fibrin-bearing MPs levels (55 / μL).
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others (anti-MUC1-FITC, Biomeda, Foster City, CA, 
USA), which could explain these different identification 
levels, the difference was probably due to an under-
expression of MUC1 by CRC and PC in our study, 
compared to the two others.
On the other hand, these two series reported also a 
correlation between elevated procoagulant activity of MPs 
and shorter overall survival [13, 22]. Indeed, Tesselaar et 
al observed significant shorter median overall survival 
in case of elevated MPs-TF activity, and in case of VTE 
associated with PC or breast cancer (2 months) than 
without VTE (4.5 and 13 months, respectively, p=0.002) 
[22]. Sherida et al noted that, in case of local PC, median 
overall survival was a significantly shorter in patients 
with high tumour-TF expression than in those with low 
tumour-TF expression (12.7 vs 25.8 months, p=0.008). 
The difference in survival was not significant for patients 
with (locally) advanced disease [13]. In our series, we 
have also reported that overall survival was shorter in 
case of thrombo-embolic event than without (median 
survival 9 vs 28 months, p=0.2), but this difference was 
not significant. Median overall survival was also shorter 
in case elevated levels of fibrin-bearing MPs (> 55 MPs/ 
μL: 14 vs 28 months, p=0.07).
Finally, we have showed that among their most 
frequent expressed genes, PC- and CRC-derived MPs 
expressed 4 identical genes (ITGB1, ANXA1, ANXA5, 
NFKB1). These genes are known to be implicated in 
metastatic diffusion of tumor cells, drug resistance, 
coagulation or inflammation. These results are in 
accordance with our previous results suggesting the 
implication of MPs in cancer-associated thrombo-embolic 
events. They suggest also the implication of MPs in tumor 
growth and inflammation. Further analyses are required to 
confirm these result in patients’ cohort, and compare gene 
expression levels with occurrence of metastasis, thrombo-
embolic event or poor survival.
The main limit of this series is its small sample size, 
and thus its lake of statistical power, which can explain 
the absence of significant difference for the separate 
comparisons of CRC and PC, and for the overall survival. 
However, there was no bias in analysis and interpretation 
of data, because preparation and analysis of circulating 
MPs was performed according to a standardized protocol 
[36]. The AUC for fibrin-bearing MPs demonstrated 
the good performance of this parameter in prediction 
of thromboembolic event (0.67; p=0.01). Moreover, we 
couldn’t perform RNA profile analyses on our patients’ 
cohort, because the samples volumes were insufficient, 
and genetic analyses required specific consent from 
patients that we didn’t ask when we started our study.
In conclusion, in our study, circulating fibrin-
bearing microparticles were more frequently observed in 
the presence of cancer-associated thrombo-embolic events 
than D-dimer. High levels of fibrin-bearing microparticles 
were associated with poor survival. Most of fibrin-bearing 
microparticles seemed to be produced by erythrocytes, 
endothelial cells or tumour cells (Ep-CAM+). The most 
frequent genes expressed by MPs derived from pancreatic 
or colorectal cancer were implicated in metastatic 
diffusion of tumor cells, drug resistance, coagulation 
or inflammation. We thus suggest that circulating 
microparticles, particularly fibrin-bearing microparticles, 
could be used as a new biomarker to predict cancer-
associated thrombo-embolic events and poor survival. 
Further larger studies are obviously required to confirm 
these results.
MATERIALS AND METHODS
Study population
We prospectively included all the patients who 
underwent surgery for CRC and PC in the Digestive 
Surgical Department of Timone’s Hospital (Marseille, 
France) between 2009 and 2013. All the individuals 
signed an institutional review board-approved consent 
form. Agreement reference of UMR-1076 tissue 
collection was DC- 2013-1815. Patients under 18 years 
of age, without informed consent, undergoing surgery for 
benign colorectal or pancreatic diseases, i.e, inflammatory 
bowel diseases or chronic pancreatitis, and those without 
pathological diagnosis of malignancy were excluded.
Collected data were demographic (age, sex), clinical 
(medical and surgical history, TNM stages of PC and 
CRC and preoperative chemoradiotherapy), laboratory 
(hemogram, levels of CEA and CA19-9). The occurrence 
of a thrombo-embolic event, such as venous (deep venous 
thrombosis, pulmonary embolism) or arterial (cerebral 
or myocardial infarct) thromboembolism, during the 
postoperative course or the follow-up, was assessed. The 
diagnosis of deep venous thrombosis was confirmed by 
duplex ultrasonography while high-probability ventilation-
perfusion lung scan and/or positive angiography 
were required to establish the diagnosis of pulmonary 
embolism. Computed tomography scan or magnetic 
resonance imaging were used to confirm the presence 
of intra-abdominal or pelvic vein thrombosis, or arterial 
cerebral infarct. Myocardial infarct was diagnosed in 
presence of elevated Troponin’s level and coronarography. 
The following thrombotic events were excluded from 
the analysis: anyone before blood sample, vascular 
access-induced thrombosis, superficial thrombophlebitis, 
thrombosis related to direct extension or compression by 
malignant tumor and thrombosis occurring in the setting 
of disseminated intravascular coagulation.
Two groups of patients were thus constituted:
- Group A: patients who presented with thrombo-
embolic event
- Group B: patients without thrombo-embolic event.
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Platelet-poor plasma (PPP) containing MPs in 
human blood
Venous fasted blood samples were obtained the day 
of the surgery, just before surgery. They were collected 
in citrated tubes, stored in vertical position and room 
temperature, and then prepared within two hours following 
the drawing, in order to avoid coagulation after blood 
collection, as described by Lacroix et al [24]. Citrated 
blood was centrifuged at 200 g for 15 minutes to obtain 
the platelet-rich plasma (PRP). Platelet Poor Plasma 
(PPP) was obtained after centrifugation of PRP at 1100 
g for 15 minutes, with prostacyclin (PGI2) added to 
prevent platelet activation. PPP was then centrifuged at 
7000 g for 3 minutes. Aliquots were snap-frozen in liquid 
nitrogen and stored at -80°C until the measurements were 
performed.
Flow cytometric analysis of PPP samples
The circulating MPs contained in the PPP samples 
were analyzed using a Gallios flow cytometer, as 
previously described by Robert et al [25]. The flow 
cytometry instrument settings and MP gating were 
performed with Megamix beads. The MP cellular origin 
was detected with a combination of Annexin V and 
specific antibodies against cells of origin. Procoagulant 
MPs were determined using a combination of Annexin 
V and antibodies directed against TF and fibrin, the 
final product of the coagulation cascade. The fibrin 
antibody was a generous gift from Pr Furie (Harvard 
Medical School, Boston). These antibodies and their 
isotype controls were labeled in-house with an Alexa 
Fluor labeling kit. Tumor MPs were characterized by 
the detection of MPs (Annexin V positive) expressing 
tumor markers on their surface, such as Mucine1 (Muc1), 
Podoplanin, CEA and CA19-9. To find the origin of fibrin-
bearing MPs, we have firstly confirmed the expression of 
Ep-CAM on MPs derived from PC cell lines (BxPC-3 and 
Capan-2); we have then characterized MPs derived from 
PC using a combination of MPs cellular origin antigens or 
Ep-CAM with fibrin.
Matched isotype control antibodies were labeled 
in-house with an Alexa fluor labeling kit. Each specific 
antibody was matched with an isotype control antibody 
labeled with an appropriate fluorescent dye. The MPs 
labeling was based on a 30-minute incubation of patient 
PPP (30 μL) with Annexin V and appropriate antibodies; 
300 μL of calcium buffer was then added to improve 
the binding of Annexin V to PS. After a 3-minute 
incubation, 100 μL of formaldehyde (16%) was added 
to fix the sample (and thus avoid coagulation), and 30 
μL of CytoCount beads was added; theses beads were 
necessary to determine the concentration of MPs in PPP. 
The concentrations are expressed as the number of MPs/ 
μL of PPP. The samples and associated controls were 
measured within an hour using a Gallios flow cytometer. 
The sample analyses were performed with Kaluza 
software [24]. We used a standardized flow cytometry 
protocol, based on fluorescent calibrated beads (0.1, 0.3, 
0.5, and 0.9 μm) called Megamix (BioCytex, Marseille, 
France). Forward scatter threshold of discriminator value 
and photomultiplier tube voltage were regularly adjusted, 
in order to reduce background noise and thus detect with 
more accuracy the different MPs subpopulations (with size 
from 0.2 to 1 μm), as reported by Robert et al [25].
D-dimer level measurement
D-dimer levels (expressed in ng/mL) were measured 
from PPP samples, using Stratus® CS Analyzer (Siemens, 
Germany).
Analysis of RNA profile PC- and CRC-derived 
MPs
MPs were obtained from human PC (BxPC-3) and 
CRC (HT29) cell lines (ATCC, Manassas, VA). Total 
RNA for quantitative RT-PCR (RT-qPCR) and microarray 
analyses was extracted from BxPC-3 or HT29 derived 
MPs using the Trizol/chloroform solution (Thermo Fisher 
Scientific, Waltham, MA) according to the manufacturer’s 
instructions. The RNA was reverse transcribed using 
Superscript IV Reverse Transcriptase, outRNase and 
oligo(dT) primers (Thermo Fisher Scientific, Waltham, 
MA). RT-qPCR reactions were performed using a 
Taqman qPCR kit (Taqman Thermo Fisher Scientific, 
Waltham, MA) and analyzed by StepOne real-time PCR 
detection system (Life Technologies, Carlsbad, CA). 
The RNA microarray experiments were performed with 
the TaqMan® Gene Signature Arrays using a Human 
Inflammation expression array (Life Technologies, 
Carlsbad, CA), which contains 96 gene types. To study 
gene expression changes between HT29 and BxPC-3 MPs, 
94 genes were selected based on an inflammation pathway 
product (Life Technologies, Carlsbad, CA). All genes 
were expressed in CT). We reported the 6 most frequently 
expressed genes normalized to 18S (expressed in delta 
CT) in the two cell lines.
Statistical analysis
The qualitative and categorical variables are 
expressed as percentages and the median with a range. The 
MPs levels, expressed as MPs/ μL, and D-dimer levels, 
expressed in ng/mL, are compared between groups using 
the Student t. All the tests were two-tailed, and differences 
were considered significant at p<0.05. In order to evaluate 
intrinsic characteristics of MPs levels, Receiving Operator 
Characteristics curve was performed with calculation 
of the AUC. All the analyses were performed using the 
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GraphPad software (Graphpad Software Inc., San Diego, 
California, USA).
Abbreviations
- VTE: venous thromboembolism
- MPs: microparticles
- TF: tissue factor
- PS: phosphatidylserine
- PC: pancreatic cancer
- CRC: colorectal cancer
- AUC: area under the curve
- PMPs: platelet-derived MPs
- EMPs: endothelial cell-derived MPs
- PDI: protein disulfide isomerase
- MUC1: mucin 1
- CEA: carcinoembryonic antigen
- CA19-9: carbohydrate antigen 19-9
- PRP: platelet-rich plasma
- PPP: Platelet Poor Plasma
- PGI2: prostacyclin
- RNA: ribonucleic acid
 - RT-PCR: reverse transcription polymerase chain 
reaction
- CT: cycle threshold.
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